NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02005471,A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL),https://clinicaltrials.gov/study/NCT02005471,MURANO,COMPLETED,"The purpose of this open-label, multicenter, randomized, Phase III study is to evaluate the benefit of venetoclax in combination with rituximab compared with bendamustine in combination with rituximab in participants with relapsed or refractory CLL. Participants will be randomly assigned in 1:1 ratio to receive either venetoclax + rituximab (Arm A) or bendamustine + rituximab (Arm B).",YES,Chronic Lymphocytic Leukemia,DRUG: Bendamustine|DRUG: Venetoclax|DRUG: Rituximab,"Percentage of Participants With PD as Assessed by the Investigator Using Standard International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Guidelines or Death, Assessment of response was performed by the investigator according to the iwCLL guidelines. PD was defined as occurrence of one of the following events: appearance of any new extra nodal lesion; new palpable lymph node (greater than \[\>\] 1.5 centimeters \[cm\]); unequivocal progression of non-target lesion; an increase of greater than or equal to (\>/=) 50 percent (%) compared to baseline in splenomegaly, hepatomegaly, number of blood lymphocytes with lymphocyte count \>/=5000 per microliter (mcL), or in longest diameter of any extra nodal lesion; transformation to a more aggressive histology; decrease of \>/=50% compared to baseline in platelet or neutrophil count; or decrease in hemoglobin level by \>2 grams per deciliter (g/dL) or to less than \[\<\] 10 g/dL. Percentages are rounded off., Baseline up to PD or death from any cause, whichever occurred first (up to approximately 8 years 5 months)|Progression-Free Survival (PFS) as Assessed by the Investigator Using Standard iwCLL Guidelines, PFS was defined as the time from randomization until first occurrence of PD/relapse as assessed by the investigator using iwCLL guidelines, or death from any cause, whichever occurred first. PD: occurrence of one of the following: new lesion; new palpable lymph node (\>1.5 cm); unequivocal progression of non-target lesion; increase of \>/=50% in splenomegaly, hepatomegaly, blood lymphocytes with count \>/=5000/mcL, longest diameter of any lesion; transformation to more aggressive histology; decrease of \>/=50% in platelet or neutrophil count, or hemoglobin level by \>2 g/dL or to \<10 g/dL. Participants who had not progressed, relapsed, or died at the time of analysis, were censored on the date of last assessment. In case of no disease assessment after baseline, PFS was censored at the time of randomization+1 day. The median PFS was estimated using Kaplan-Meier method and the 95% confidence interval (CI) was computed using method of Brookmeyer and Crowley., Baseline up to PD or death, whichever occurred first (up to approximately 8 years 5 months)","Percentage of Participants With PD or Death as Assessed by the Independent Review Committee (IRC) Using Standard iwCLL Guidelines, Assessment of response was performed by the IRC according to the iwCLL guidelines. PD was defined as occurrence of one of the following events: appearance of any new extra nodal lesion; new palpable lymph node (\>1.5 cm); unequivocal progression of non-target lesion; an increase of \>/=50% compared to baseline in splenomegaly, hepatomegaly, number of blood lymphocytes with lymphocyte count \>/=5000/mcL, or in longest diameter of any extra nodal lesion; transformation to a more aggressive histology; decrease of \>/=50% compared to baseline in platelet or neutrophil count; or decrease in hemoglobin level by \>2 g/dL or to \<10 g/dL. No new IRC data was generated post the primary analysis., Baseline up to PD or death, whichever occurred first (up to approximately 3 years)|PFS as Assessed by the IRC Using Standard iwCLL Guidelines, PFS was defined as the time from randomization until first occurrence of PD/relapse as assessed by the IRC using iwCLL guidelines, or death from any cause, whichever occurred first. PD: occurrence of one of the following: new lesion; new palpable lymph node (\>1.5 cm); unequivocal progression of non-target lesion; increase of \>/=50% in splenomegaly, hepatomegaly, blood lymphocytes with count \>/=5000/mcL, longest diameter of any lesion; transformation to more aggressive histology; decrease of \>/=50% in platelet or neutrophil count, or hemoglobin level by \>2 g/dL or to \<10 g/dL. Participants who had not progressed, relapsed, or died at the time of analysis, were censored on the date of last assessment. In case of no disease assessment after baseline, PFS was censored at the time of randomization+1 day. The median PFS was estimated using Kaplan-Meier method and the 95% CI was computed using method of Brookmeyer and Crowley. No new IRC data was generated post the primary analysis., Baseline up to PD or death, whichever occurred first (up to approximately 3 years)|Percentage of Participants With PD or Death as Assessed by the Investigator Using Standard iwCLL Guidelines in Participants With 17p Deletion as Identified by Fluorescence In-situ Hybridization (FISH) Test, Assessment of response was performed by the investigator according to the iwCLL guidelines. PD was defined as occurrence of one of the following events: appearance of any new extra nodal lesion; new palpable lymph node (\>1.5 cm); unequivocal progression of non-target lesion; an increase of \>/=50% compared to baseline in splenomegaly, hepatomegaly, number of blood lymphocytes with lymphocyte count \>/=5000/mcL, or in longest diameter of any extra nodal lesion; transformation to a more aggressive histology; decrease of \>/=50% compared to baseline in platelet or neutrophil count; or decrease in hemoglobin level by \>2 g/dL or to \<10 g/dL. Percentages are rounded off., Baseline up to PD or death, whichever occurred first (up to approximately 8 years 5 months)|PFS as Assessed by the Investigator Using Standard iwCLL Guidelines in Participants With 17p Deletion as Identified by FISH Test, PFS was defined as the time from randomization until first occurrence of PD/relapse as assessed by the investigator using iwCLL guidelines, or death from any cause, whichever occurred first. PD: occurrence of one of the following: new lesion; new palpable lymph node (\>1.5 cm); unequivocal progression of non-target lesion; increase of \>/=50% in splenomegaly, hepatomegaly, blood lymphocytes with count \>/=5000/mcL, longest diameter of any lesion; transformation to more aggressive histology; decrease of \>/=50% in platelet or neutrophil count, or hemoglobin level by \>2 g/dL or to \<10 g/dL. Participants who had not progressed, relapsed, or died at the time of analysis, were censored on the date of last assessment. In case of no disease assessment after baseline, PFS was censored at the time of randomization+1 day. The median PFS was estimated using Kaplan-Meier method and the 95% CI was computed using method of Brookmeyer and Crowley., Baseline up to PD or death, whichever occurred first (up to approximately 8 years 5 months)|Percentage of Participants With PD or Death as Assessed by the IRC Using Standard iwCLL Guidelines in Participants With 17p Deletion as Identified by FISH Test, Assessment of response was performed by the IRC according to the iwCLL guidelines. PD was defined as occurrence of one of the following events: appearance of any new extra nodal lesion; new palpable lymph node (\>1.5 cm); unequivocal progression of non-target lesion; an increase of \>/=50% compared to baseline in splenomegaly, hepatomegaly, number of blood lymphocytes with lymphocyte count \>/=5000/mcL, or in longest diameter of any extra nodal lesion; transformation to a more aggressive histology; decrease of \>/=50% compared to baseline in platelet or neutrophil count; or decrease in hemoglobin level by \>2 g/dL or to \<10 g/dL. No new IRC data was generated post the primary analysis., Baseline up to PD or death, whichever occurred first (up to approximately 3 years)|PFS as Assessed by the IRC Using Standard iwCLL Guidelines in Participants With 17p Deletion as Identified by FISH Test, PFS was defined as the time from randomization until first occurrence of PD/relapse as assessed by the IRC using iwCLL guidelines, or death from any cause, whichever occurred first. PD: occurrence of one of the following: new lesion; new palpable lymph node (\>1.5 cm); unequivocal progression of non-target lesion; increase of \>/=50% in splenomegaly, hepatomegaly, blood lymphocytes with count \>/=5000/mcL, longest diameter of any lesion; transformation to more aggressive histology; decrease of \>/=50% in platelet or neutrophil count, or hemoglobin level by \>2 g/dL or to \<10 g/dL. Participants who had not progressed, relapsed, or died at the time of analysis, were censored on the date of last assessment. In case of no disease assessment after baseline, PFS was censored at the time of randomization+1 day. The median PFS was estimated using Kaplan-Meier method and the 95% CI was computed using method of Brookmeyer and Crowley. No new IRC data was generated post the primary analysis., Baseline up to PD or death, whichever occurred first (up to approximately 3 years)|Percentage of Participants With Best Overall Response of Complete Response (CR), CR With Incomplete Bone Marrow Recovery (CRi), Nodular Partial Response (nPR), or Partial Response (PR) as Assessed by the Investigator Using iwCLL Guidelines, Response was assessed by investigator according to iwCLL guidelines and was confirmed by repeat assessment \>/=4 weeks after initial documentation. CR: peripheral blood lymphocytes \<4000/mcL; absence of any new lesion, nodal disease, lymphadenopathy, hepatomegaly, splenomegaly, and constitutional symptoms; neutrophils \>1500/mcL, platelets \>100000/mcL, hemoglobin \>11.0 g/dL without need for transfusion or exogenous growth factors; normocellular bone marrow with \<30% lymphocytes; no lymphoid nodules. CRi: fulfilling all CR criteria but persistent cytopenia. PR: \>/=50% reduction in two of following: peripheral blood lymphocytes, lymphadenopathy, spleen and/or liver enlargement; and 1 of following: neutrophils \>1500/mcL, platelets \>100000/mcL, hemoglobin \>11.0 g/dL or \>/=50% improvement without need for transfusion or exogenous growth factors. nPR: fulfilling all CR criteria but presence of lymphoid nodules. 95% CI was computed using Pearson-Clopper method.Percentages are rounded off., Baseline up to approximately 8 years 5 months|Percentage of Participants With Best Overall Response of CR, CRi, nPR, or PR as Assessed by the IRC Using iwCLL Guidelines, Response was assessed by IRC according to iwCLL guidelines and was confirmed by repeat assessment \>/=4 weeks after initial documentation. CR: peripheral blood lymphocytes \<4000/mcL; absence of any new lesion, nodal disease, lymphadenopathy, hepatomegaly, splenomegaly, constitutional symptoms; neutrophils \>1500/mcL, platelets \>100000/mcL, hemoglobin \>11.0 g/dL without need for transfusion or exogenous growth factors; normocellular bone marrow with \<30% lymphocytes; no lymphoid nodules. CRi: fulfilling all CR criteria but persistent cytopenia. PR: \>/=50% reduction in 2 of following: peripheral blood lymphocytes, lymphadenopathy, spleen and/or liver enlargement; 1 of following: neutrophils \>1500/mcL, platelets \>100000/mcL, hemoglobin \>11.0 g/dL or \>/=50% improvement without need for transfusion or exogenous growth factors. nPR: fulfilling all CR criteria but presence of lymphoid nodules. 95% CI was computed using Pearson-Clopper method.No new IRC data was generated post primary analysis., Baseline up to last FUV (up to approximately 3 years)|Percentage of Participants With Overall Response of CR, Cri, nPR, or PR at End of Combination Treatment Visit as Assessed by the Investigator Using iwCLL Guidelines, Response was assessed by investigator according to iwCLL guidelines and was confirmed by repeat assessment \>/=4 weeks after initial documentation. CR: peripheral blood lymphocytes \<4000/mcL; absence of any new lesion, nodal disease, lymphadenopathy, hepatomegaly, splenomegaly, and constitutional symptoms; neutrophils \>1500/mcL, platelets \>100000/mcL, hemoglobin \>11.0 g/dL without need for transfusion or exogenous growth factors; normocellular bone marrow with \<30% lymphocytes; no lymphoid nodules. CRi: fulfilling all CR criteria but persistent cytopenia. PR: \>/=50% reduction in 2 of following: peripheral blood lymphocytes, lymphadenopathy, spleen and/or liver enlargement; and 1 of following: neutrophils \>1500/mcL, platelets \>100000/mcL, hemoglobin \>11.0 g/dL or \>/=50% improvement without need for transfusion or exogenous growth factors. nPR: fulfilling all CR criteria but presence of lymphoid nodules. 95% CI was computed using Pearson-Clopper method. Percentages are rounded off., End of combination treatment response (EoCTR) visit (8 to 12 weeks after Cycle [C] 6 Day [1]); Cycle length = 28 days|Percentage of Participants With Overall Response of CR, Cri, nPR, or PR at End of Combination Treatment Visit as Assessed by the IRC Using iwCLL Guidelines, Response was assessed by the IRC according to the iwCLL guidelines and was confirmed by repeat assessment \>/=4 weeks after initial documentation. CR: peripheral blood lymphocytes \<4000/mcL; absence of any new lesion, nodal disease, lymphadenopathy, hepatomegaly, splenomegaly, and constitutional symptoms; neutrophils \>1500/mcL, platelets \>100000/mcL, hemoglobin \>11.0 g/dL without need for transfusion or exogenous growth factors; normocellular bone marrow with \<30% lymphocytes; no lymphoid nodules. CRi: fulfilling all CR criteria but persistent cytopenia. PR: \>/=50% reduction in two of the following: peripheral blood lymphocytes, lymphadenopathy, spleen and/or liver enlargement; and one of the following: neutrophils \>1500/mcL, platelets \>100000/mcL, hemoglobin \>11.0 g/dL or \>/=50% improvement without need for transfusion or exogenous growth factors. nPR: fulfilling all CR criteria but presence of lymphoid nodules. The 95% CI was computed using Pearson-Clopper method., EoCTR visit (8 to 12 weeks after C6D1); Cycle length = 28 days|Percentage of Participants Who Died, Percentage of participants who died from any cause, during the study, was reported. Percentage is rounded off., Baseline up to approximately 8 years 5 months|Overall Survival (OS), OS was defined as the time from the date of randomization to the date of death from any cause. Participants alive at the time of the analysis were censored at the date when they were last known to be alive as documented by the investigator. The median OS was estimated using Kaplan-Meier method and the 95% CI was computed using method of Brookmeyer and Crowley., Baseline up to approximately 8 years 5 months|Percentage of Participants With PD/Relapse, Start of a New Anti-Chronic Lymphocytic Leukemia (CLL) Therapy, or Death as Assessed by the Investigator Using iwCLL Guidelines, Percentage of participants with PD/relapse, death from any cause, or start of a new non-protocol-specified anti-CLL therapy as assessed by the investigator, during the study, was reported. PD was defined as occurrence of one of the following events: appearance of any new extra nodal lesion; new palpable lymph node (\>1.5 cm); unequivocal progression of non-target lesion; an increase of \>/=50% compared to baseline in splenomegaly, hepatomegaly, number of blood lymphocytes with lymphocyte count \>/=5000/mcL, or in longest diameter of any extra nodal lesion; transformation to a more aggressive histology; decrease of \>/=50% compared to baseline in platelet or neutrophil count; or decrease in hemoglobin level by \>2 g/dL or to \<10 g/dL. Percentages are rounded off., Baseline up to PD/relapse, start of a new anti-CLL therapy, or death from any cause, whichever occurred first (approximately 8 years 5 months)|Event-Free Survival (EFS) as Assessed by the Investigator Using iwCLL Guidelines, EFS was defined as the time from date of randomization until the date of PD/relapse, start of a new non-protocol-specified anti-CLL therapy, or death from any cause, whichever occurred first, as assessed by the investigator. PD: occurrence of one of the following: new lesion; new palpable lymph node (\>1.5 cm); unequivocal progression of non-target lesion; increase of \>/=50% in splenomegaly, hepatomegaly, blood lymphocytes with count \>/=5000/mcL, longest diameter of any lesion; transformation to more aggressive histology; decrease of \>/=50% in platelet or neutrophil count, or hemoglobin level by \>2 g/dL or to \<10 g/dL. Participants without any of the specified event at the time of analysis were censored at the date of last adequate response assessment. In case of no post-baseline response assessment, participants were censored at the randomization date. The median EFS was estimated using Kaplan-Meier method and the 95% CI was computed using method of Brookmeyer and Crowley., Baseline up to PD/relapse, start of a new anti-CLL therapy, or death from any cause, whichever occurred first (approximately 8 years 5 months)|Percentage of Participants With PD or Death Among Participants With Best Overall Response of CR, CRi, nPR, or PR as Assessed by the Investigator Using iwCLL Guidelines, Percentage of participants with PD as assessed by the investigator according to the iwCLL guidelines or death from any cause during the study was reported. PD was defined as occurrence of one of the following events: appearance of any new extra nodal lesion; new palpable lymph node (\>1.5 cm); unequivocal progression of non-target lesion; an increase of \>/=50% compared to baseline in splenomegaly, hepatomegaly, number of blood lymphocytes with lymphocyte count \>/=5000/mcL, or in longest diameter of any extra nodal lesion; transformation to a more aggressive histology; decrease of \>/=50% compared to baseline in platelet or neutrophil count; or decrease in hemoglobin level by \>2 g/dL or to \<10 g/dL. CR, CRi, nPR, and PR have been defined in previous outcomes, and are not repeated here due to space constraint. Percentage is rounded off., From time of achieving best overall response until PD or death from any cause, whichever occurred first (up to approximately 8 years 5 months)|Duration of Responses (DOR) as Assessed by the Investigator Using iwCLL Guidelines, DOR was defined as the time from first occurrence of a documented response of CR, CRi, nPR, or PR until PD/relapse, as assessed by the investigator according to the iwCLL guidelines, or death from any cause. PD: occurrence of one of the following: new lesion; new palpable lymph node (\>1.5 cm); unequivocal progression of non-target lesion; increase of \>/=50% in splenomegaly, hepatomegaly, blood lymphocytes with count \>/=5000/mcL, longest diameter of any lesion; transformation to more aggressive histology; decrease of \>/=50% in platelet or neutrophil count, or hemoglobin level by \>2 g/dL or to \<10 g/dL. Participants without PD or death after response were censored at the last date of adequate response assessment. The median DOR was estimated using Kaplan-Meier method and the 95% CI was computed using method of Brookmeyer and Crowley. CR, CRi, nPR, and PR have been defined in previous outcomes, and are not repeated here due to space constraint., From time of achieving best overall response until PD or death from any cause, whichever occurred first (up to approximately 8 years 5 months)|Percentage of Participants With Start of New Anti-CLL Treatment or Death as Assessed by the Investigator, Percentage of participants with start of new non-protocol-specified anti-CLL therapy, as assessed by the investigator, or death from any cause, during the study, was reported. Percentage is rounded off., Baseline up to start of new ani-CLL therapy or death, whichever occurred first (up to approximately 8 years 5 months)|Time to New Anti-CLL Treatment (TTNT) as Assessed by the Investigator, TTNT was defined as the time from randomization until start of new non-protocol-specified anti-CLL treatment or death from any cause. Participants without the event at the time of analysis were censored at the last visit date for this outcome measure analysis. The median TTNT was estimated using Kaplan-Meier method and the 95% CI was computed using method of Brookmeyer and Crowley., Baseline up to start of new ani-CLL therapy or death, whichever occurred first (up to approximately 8 years 5 months)|Percentage of Participants With Minimal Residual Disease (MRD) Negativity in Peripheral Blood, MRD-negativity was defined as the presence of \<1 malignant B-cell per 10000 normal B-cells in a sample of at least 200000 B-cells, as assessed by the allele specific oligonucleotide polymerase chain reaction (ASO-PCR) and/or flow cytometry technique. Percentage of participants with MRD-negativity was reported. The 95% CI was computed using Pearson-Clopper method. Percentage is rounded off., EoCTR visit (8 to 12 weeks after C6D1); Cycle length = 28 days|Percentage of Participants With MRD Negativity in Bone Marrow, MRD-negativity was defined as the presence of \<1 malignant B-cell per 10000 normal B-cells in a sample of at least 200000 B-cells, as assessed flow cytometry technique. Percentage of participants with MRD-negativity was reported. The 95% CI was computed using Pearson-Clopper method. Percentages are rounded off., EoCTR visit (8 to 12 weeks after C6D1); Cycle length = 28 days|Plasma Venetoclax Concentrations, Pre-dose (0 hour, anytime before venetoclax administration) and 4 hours post-dose on D1 of Cycles 1 and 4; Cycle length = 28 days|Change From Baseline in Monroe Dunaway (MD) Anderson Symptom Inventory (MDASI) Core Symptom Severity, Module Symptom Severity, and Interference Scores, MDASI is a 25-item validated questionnaire consisting of 2 parts. Part 1: 19-items divided into 2 scales, Core Symptom Severity (average of Questions 1 to 13; total 13 items: pain, fatigue, nausea, disturbed sleep, distress, shortness of breath, remembering things, lack of appetite, drowsiness, dry mouth, sadness, vomiting, and numbness) and Module Symptom Severity (average of Questions 14 to 19; total 6 items: night sweats, fevers and chills, lymph node swelling, diarrhea, bruising easy or bleeding, and constipation). Part 2: 6-items to assess Interference (symptom distress) (average of Questions 20 to 25; total 6 items: general activity, walking, work, mood, relations with other people, and enjoyment of life). Each item was rated from 0 to 10, with lower scores indicating better outcome. Total score for Core Symptom Severity, Module Symptom Severity, and Interference are reported which range from 0 to 10, with lower scores indicating better health-related quality of life (HRQoL)., Baseline, Days 1, 8, and 15 of Cycles 1, 2, and 3; Cycle length = 28 days|Change From Baseline in HRQoL as Measured by European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) Functional Scales Score and Global Health Status/Global Quality-of-Life (QoL) Scale Score, EORTC QLQ-C30 is a validated self-report measure consisting of 30 questions incorporated into 5 functional scales (Physical, Role, Cognitive, Emotional, and Social), 3 symptom scales (fatigue, pain, nausea, and vomiting), a global health status/global QoL scale, and single items (dyspnea, appetite loss, sleep disturbance, constipation, and diarrhea). Most questions used 4-point scale (1='Not at all' to 4='Very much'), while 2 questions used 7-point scale (1='very poor' to 7='Excellent'). Scores were averaged, transformed to 0-100 scale; where higher score for functional scales=poor level of functioning; higher score for global health status/global QoL=better HRQoL., Baseline, D1 of Cycles 1, 2, 3, 4, 5, 6, STC/EW visit (up to C6D28), EoCTR visit (8 to 12 weeks after C6D1), and FUVs (every 12 weeks after EoCTR up to 3 years); Cycle length = 28 days|Change From Baseline in HRQoL as Measured by Quality of Life Questionnaire Associated CLL Module (QLQ-CLL16) Multi-Item Scales Score, The EORTC QLQ-CLL16 module is designed for participants with Stage 0 to Stage 4 CLL. It is composed of 16 questions and there are four multi-item scales on Fatigue (2 items), Treatment-related side effects (TRSE, 4 items), Disease-related symptoms (DRS, 4 items), and Infection (4 items); and two single-item scales on social activities and future health worries. Multi-item scales score are reported and the total score for each multi-item scale was transformed to result in a total score range of 0 to 100, where higher score = poor HRQoL., Baseline, D1 of Cycles 1, 2, 3, 4, 5, 6, STC/EW visit (up to C6D28), EoCTR visit (8 to 12 weeks after C6D1), and FUVs (every 12 weeks after EoCTR up to 3 years); Cycle length = 28 days|Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs), An AE was defined as any untoward medical occurrence in a participant administered with Mircera and which does not necessarily have a causal relationship with Mircera. A Serious Adverse Event (SAE) is any significant hazard, contraindication, side effect that is fatal or life threatening; requires in-patient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is medically significant or requires intervention to prevent one or other of the outcomes listed above. AEs were assessed using National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0 (NCI CTCAE, v4.0), From signing of informed consent form up to approximately 8 years 5 months|Number of Participants With Grade 3 or Higher Tumor Lysis Syndrome (TLS) and Infusion-related Reactions (IRRs), An AE was defined as any untoward medical occurrence in a participant administered with Mircera and which does not necessarily have a causal relationship with Mircera. A SAE is any significant hazard, contraindication, side effect that is fatal or life threatening; requires in-patient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is medically significant or requires intervention to prevent one or other of the outcomes listed above. TLS and IRRs were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE v4.0). Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe or medically significant; Grade 4 = Life-threatening; Grade 5 = Death. A higher grade indicates a worse outcome., From signing of informed consent form up to approximately 8 years 5 months","Change From Baseline in Lymphocyte Subset Counts at Specified Time Points, Baseline, C4D14-28, Study Treatment Completion/Early Withdrawal (STC/EW, up to C6D28), EoCTR visit (8 to 12 weeks after C6D1), and at FUVs (every 12 weeks after EoCTR up to 3 years); Cycle length = 28 days",Hoffmann-La Roche,AbbVie,ALL,"ADULT, OLDER_ADULT",PHASE3,389,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,GO28667|2013-002110-12,2014-03-17,2017-05-08,2022-08-03,2013-12-09,2018-10-01,2023-10-17,"University of California San Diego Medical Center, La Jolla, California, 92093-5354, United States|Henry Ford Health System, Detroit, Michigan, 48202, United States|Memorial Sloan Kettering Cancer Center; Clinical Trials Office, New York, New York, 10021, United States|Perlmutter Cancer Center NYU Langone Health, New York, New York, 10032, United States|Huntsman Cancer Institute; University of Utah, Salt Lake City, Utah, 84112, United States|The Canberra Hospital, Garran, Australian Capital Territory, 2065, Australia|Concord Repatriation General Hospital, Concord, New South Wales, 2139, Australia|St George Hospital, Kogarah, New South Wales, New South Wales, 2217, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, 4102, Australia|Royal Adelaide Hospital, Adelaide, South Australia, 5000, Australia|Flinders Medical Centre, Bedford Park, South Australia, 5042, Australia|Royal Hobart Hospital, Hobart, Tasmania, 7000, Australia|Frankston Hospital, Frankston, Victoria, 3199, Australia|Monash Medical Centre; Haematology, Melbourne, Victoria, 3168, Australia|Slade Health Pharmacy, Mount Waverley, Victoria, 3149, Australia|Peter MacCallum Cancer Center, North Melbourne, Victoria, 3051, Australia|Royal Melbourne Hospital, Parkville, Victoria, 3050, Australia|The Perth Blood Institute, Nedlands, Western Australia, 6009, Australia|Medizinische Universität Innsbruck, Innsbruck, 6020, Austria|LKH - Universitätsklinikum der PMU Salzburg, Salzburg, 5020, Austria|Medizinische Universität Wien, Wien, 1090, Austria|Klinik Ottakring, Wien, 1160, Austria|ZNA Antwerpen; Department Hematology, Antwerpen, 2060, Belgium|Cliniques Universitaires Saint-Luc; Hematology, Bruxelles, 1200, Belgium|AZ Groeninge, Kortrijk, 8500, Belgium|UZ Leuven; Department Hematology, Leuven, 3000, Belgium|CHU UCL Mont-Godinne, Mont-godinne, 5530, Belgium|AZ Delta (Campus Rumbeke), Roeselare, 8800, Belgium|Foothills Medical Centre; Centre Dept of Medical Clinical Neuroscience, Calgary, Alberta, T2N 2T9, Canada|Juravinski Cancer Clinic, Hamilton, Ontario, L8N 3Z5, Canada|Jewish General Hospital, Montreal, Quebec, H3T 1E2, Canada|Saskatoon City Hospital;Saskatchewan Cancer Centre, Saskatoon, Saskatchewan, S7N 4H4, Canada|Fakultni nemocnice Brno, Brno, 613 00, Czechia|Fakultni nemocnice Hradec Kralove, Hradec Kralove, 500 05, Czechia|Fakultní nemocnice Olomouc, Olomouc, 775 20, Czechia|Fakultni nemocnice Ostrava, Ostrava - Poruba, 708 52, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, 128 08, Czechia|Fakultni nemocnice Kralovske Vinohrady, Praha, 100 34, Czechia|Herlev Hospital, Herlev, 2730, Denmark|Rigshospitalet, København Ø, 2100, Denmark|Odense Universitetshospital, Odense C, 5000, Denmark|Sjællands Universitetshospital, Roskilde, Roskilde, 4000, Denmark|Sygehus Lillebælt, Vejle, Vejle, 7100, Denmark|Hôpital Morvan, Brest, 29609, France|Centre Hospitalier Départemental Les Oudairies, La Roche sur Yon, 85925, France|Hopital Claude Huriez - CHU Lille, Lille, 59037, France|Hopital Saint Eloi, Montpellier, 34295, France|CHU Nantes - Hôtel Dieu; Service Assistance Medicale à la Procreation, Nantes, 44093, France|Hopital Robert Debre, Paris, 75019, France|Centre Hospitalier Lyon Sud, Pierre Benite, 69495, France|CHU Poitiers - Hopital La Miletrie, Poitiers, 86000, France|CHU de Rennes - Hopital de Pontchaillo, Rennes, 35033, France|Centre Henri Becquerel, Rouen, 76038, France|Institut Universitaire du Cancer - Oncopole Toulouse (IUCT-O), Toulouse, 31059, France|CHU Tours - Hôpital Bretonneau, Tours, 37044, France|Hôpital de Brabois Adultes, Vandoeuvre-les-nancy, 54511, France|Universitätsklinikum ""Carl Gustav Carus"" der Technischen Universität Dresden, Dresden, 01307, Germany|Universitaetsklinikum Freiburg, Freiburg, 79106, Germany|Universitätsklinikum Tübingen, Tübingen, 72076, Germany|Semmelweis Egyetem, Budapest, 1088, Hungary|Orszagos Onkologiai Intezet, Budapest, 1122, Hungary|Debreceni Egyetem Klinikai Központ; B?rgyógyászati Klinika, Debrecen, 4012, Hungary|Somogy Megyei Kaposi Mor Oktato Korhaz, Pecs, 7624, Hungary|Szegedi Tud.Egyetem Szent-Gyorgyi Albert Klin.Kozp., Szeged, 6720, Hungary|Azienda Ospedaliera Città della Salute e della Scienza di Torino; Radiology, Torino, Abruzzo, 10126, Italy|Azienda Ospedaliero Universitaria San Martino, Genova, Liguria, 16132, Italy|Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII), Bergamo, Lombardia, 24127, Italy|Ospedale San Raffaele, Milano, Lombardia, 20132, Italy|Asst Grande Ospedale Metropolitano Niguarda; SC Farmacia Ospedale, Milano, Lombardia, 20162, Italy|Azienda Ospedaliero Universitaria Ospedali Riuniti, Torrette Di Ancona, Marche, 60126, Italy|Istituto Tumori Giovanni Paolo II IRCCS Ospedale Oncologico Bari, Bari, Puglia, 70124, Italy|Azienda Ospedaliera Universitaria Careggi, Florence, Toscana, 50134, Italy|Azienda Ospedaliera Di Padova, Padova, Veneto, 35128, Italy|Seoul National University Bundang Hospital, Seongnam-si, 463-707, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, 03722, Korea, Republic of|Konkuk University Medical Center, Seoul, 05030, Korea, Republic of|The Catholic University of Korea Seoul St. Mary?s Hospital, Seoul, 6591, Korea, Republic of|Amsterdam UMC, Locatie VUMC; Neurology, Amsterdam, 1081 HV, Netherlands|Amsterdam UMC Location AMC, Amsterdam, 1105 AZ, Netherlands|Albert Schweitzer Ziekenhuis, Dordwijk; Internal Medicine, Hemato-Oncology, Dordrecht, 3318 AT, Netherlands|Medisch Spectrum Twente, Enschede, 7512 KZ, Netherlands|Leids Universitair Medisch Centrum; Cardiology, Leiden, 2333 ZA, Netherlands|Erasmus Medisch Centrum, Rotterdam, 3000 CA, Netherlands|UMC Utrecht, Utrecht, 3508, Netherlands|North Shore Hospital; Haematolgy, Auckland, 1309, New Zealand|Middlemore Hospital, Auckland, New Zealand|Christchurch Hospital NZ, Christchurch, 8011, New Zealand|Baxter Healthcare, Mount Wellington, 1060, New Zealand|SP ZOZ Zespol Szpitali Miejskich w Chorzowie, Chorzow, 41-500, Poland|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Wojewódzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi, Lodz, 93-513, Poland|Szpital Wojewodzki w Opolu, Opole, 45-061, Poland|MTZ Clinical Research Sp. z o.o., Warszawa, 02-106, Poland|Samodzielny Publiczny Szpital Kliniczny nr 1, Zabrze, 44803, Poland|FSBSI ""Russian Oncological Scientific Center n.a. N.N. Blokhin"", Moscow, Moskovskaja Oblast, 115478, Russian Federation|SRI of Hematology and Transfusiology, Sankt-peterburg, Sankt Petersburg, 191024, Russian Federation|North-West Federal Medical Research Center n.a. V.A. Almazov, St. Petersburg, Sankt Petersburg, 197341, Russian Federation|Kemerovo Regional Clinical Hospital, Kemerovo, 650066, Russian Federation|BHI of Omsk region Clinical Oncology Dispensary, Omsk, 644013, Russian Federation|Complejo Hospitalario de Navarra, Pamplona, Navarra, 31008, Spain|Hospital Universitari Vall d'Hebron, Barcelona, 08035, Spain|Hospital Clinic i Provincial de Barcelona; Hematology, Barcelona, 08036, Spain|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain|Hospital Clinico Universitario de Salamanca, Salamanca, 37007, Spain|Skånes Universitetssjukhus, Lund, 221 85, Sweden|Akademiska Sjukhuset, Uppsala, 751 85, Sweden|National Taiwan University Hospital, Taipei, 10002, Taiwan|Bristol Haematology and Oncology centre, Bristol, BS2 8ED, United Kingdom|The Christie, Manchester, M20 4BX, United Kingdom|Southampton General Hospital, Southampton, SO16 6YD, United Kingdom|Singleton Hospital; Pharmacy Department, Swansea, SA2 8QA, United Kingdom","Study Protocol, https://cdn.clinicaltrials.gov/large-docs/71/NCT02005471/Prot_002.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/71/NCT02005471/SAP_001.pdf"
